ArticleRadiological physics and technology2025
Impact of iso-dose levels on pre-treatment quality assurance in volumetric modulated arc therapy.
Article in Radiological physics and technology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The current standard of modern radiotherapy pre-treatment evaluation of dose distributions measured using gamma pass percentage is the predominant metric for Patient-Specific Quality Assurance (PSQA). The aim of the study was to analyze the impact of the different dose levels for three different gamma criteria in various anatomical sites. Retrospectively selected 120 VMAT plans of the brain, head and neck, thorax, and pelvic sites were considered for this study. Quality assurance plans were created and measurements were done using PTW Octavius 4D phantom. Three different gamma criteria were used to evaluate different dose levels' volume gamma passing rates. The maximum gamma passing rate for all dose levels except 100% with a 3%/3 mm criterion was observed for the pelvis site. A significant variation in dose levels was observed with the 3%/2 mm gamma criteria for head and neck sites, particularly above the 85% dose level compared to other anatomical sites. Using 2%/2 mm gamma criteria, there was a rapid fall in the gamma passing rate and all the dose levels showed a significant variation among different sites. This study demonstrated significant variations in gamma passing rates across anatomical sites and dose levels, emphasizing the importance of tailored QA protocols. The findings underscore the need for site-specific action limits and highlight the sensitivity of stricter gamma criteria for detecting errors in complex treatment plans.
Indexed as
Identifiers
40169512What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.